Contact RQMIS to discuss your regulatory and reimbursement planning needs.
Regulatory Strategy is Only Half the Equation
Building a successful medical product requires more than innovative technology. It requires a clear path to regulatory authorization, market access, and financial sustainability.
Developing a new medical product is a significant undertaking. Companies invest substantial resources in research, engineering, clinical development, testing, and manufacturing, often spending years preparing their technology for commercialization.
Yet one of the most consequential mistakes a medical product company can make is focusing almost exclusively on obtaining regulatory approval without considering how the product will be paid for once it reaches the market.
A medical device may receive FDA clearance, obtain CE marking in Europe, or secure authorization from Health Canada, but these milestones do not automatically translate into commercial success.
Healthcare providers must be willing to adopt the technology. Hospitals and healthcare systems must understand its clinical and economic value. Insurers, government healthcare programs, and other payers must have a viable mechanism for covering or funding its use.
Regulatory authorization establishes the conditions under which a medical product can be legally marketed. Reimbursement and market access planning help establish whether customers can realistically adopt and pay for that product.
For companies preparing to enter the United States, United Kingdom, European Union, Canada, or other international markets, these two strategies should be developed together, ideally before major product development and clinical investment decisions are made.
A Regulatory Pathway Strategy provides a structured roadmap for bringing a medical product from development to commercialization while meeting the requirements of the intended markets.
It begins with fundamental questions:
These questions are particularly important because regulatory requirements differ across international markets.
Medical devices may require a 510(k) submission, De Novo classification request, Premarket Approval (PMA), or another applicable regulatory pathway. Some devices may be exempt from premarket submission requirements, although other regulatory obligations may still apply.
An early regulatory assessment helps manufacturers understand device classification, potential predicates, evidence requirements, and whether engagement with the FDA through the Q-Submission Program would be beneficial.
Medical devices and in vitro diagnostic products must meet applicable requirements under the Medical Device Regulation (MDR) or In Vitro Diagnostic Regulation (IVDR).
Manufacturers must evaluate device classification, conformity assessment requirements, clinical or performance evidence, technical documentation, quality management systems, and post-market responsibilities.
For many products, Notified Body involvement is required before CE marking can be achieved.
The United Kingdom has its own medical device regulatory framework, with requirements that depend on the market being entered, the applicable regulations, and the product type.
Manufacturers must consider MHRA registration, conformity assessment requirements, UK Responsible Person obligations where applicable, and the evolving regulatory environment, including the distinctions between Great Britain and Northern Ireland.
Medical devices are classified into four risk categories, with Class II, III, and IV devices generally requiring a Medical Device Licence before sale.
Manufacturers must also consider applicable quality management requirements, including Medical Device Single Audit Program (MDSAP) certification where required.
A well-developed regulatory strategy helps companies anticipate these requirements and coordinate their product development activities across multiple markets.
Without an established regulatory pathway, companies risk designing products that do not fully address the evidence, documentation, testing, or quality requirements necessary for commercialization.
The consequences may include additional testing, product redesign, delayed submissions, unexpected clinical studies, and increased development expenses.
Early planning helps reduce these risks by aligning engineering, clinical, quality, and regulatory activities around a clearly defined commercialization objective.
Regulatory authorization is a critical milestone, but it does not guarantee that hospitals, physicians, patients, or healthcare systems will purchase or use a medical product.
This is where Insurance Reimbursement and Market Access Planning become essential.
A reimbursement strategy evaluates how a medical product, procedure, diagnostic test, or associated healthcare service may be funded within the healthcare systems of the intended markets.
It addresses questions such as:
The answers can significantly influence product design, clinical development, commercial positioning, and investment decisions.
In the United States, reimbursement planning commonly involves three interconnected considerations:
Coding: Identifying applicable CPT, HCPCS, ICD-10, or other coding mechanisms associated with the product, service, or procedure.
Coverage: Determining whether Medicare, Medicaid, and commercial insurance providers may cover the technology or associated services under applicable policies and medical necessity criteria.
Payment: Evaluating the payment mechanisms and reimbursement levels available to healthcare providers or facilities.
These are separate considerations. The existence of a billing code does not automatically establish insurance coverage, and coverage does not necessarily ensure that payment will be sufficient to support adoption.
For innovative technologies, companies may need to develop additional clinical evidence, pursue coding changes, engage with payers, or establish alternative commercialization approaches.
Understanding these requirements early can prevent companies from discovering significant financial barriers after receiving regulatory authorization.
Although the EU provides a common regulatory framework for medical devices through MDR and IVDR, reimbursement and healthcare funding decisions remain largely the responsibility of individual Member States.
A device that achieves CE marking may still face different market access requirements in Germany, France, Spain, Italy, and other European countries.
Depending on the country and technology, companies may need to address health technology assessment, national or regional reimbursement decisions, hospital procurement processes, and clinical or economic evidence requirements.
Consequently, obtaining CE marking should be viewed as an important regulatory milestone rather than a guarantee of reimbursement or market adoption across Europe.
In the United Kingdom, companies must consider how their products may be adopted and funded within the National Health Service (NHS) and other healthcare settings.
Depending on the technology, evaluation may involve the National Institute for Health and Care Excellence (NICE), NHS commissioning and procurement processes, and other applicable assessment mechanisms.
Demonstrating clinical benefit is important, but evidence of cost-effectiveness, operational efficiency, improved patient outcomes, and healthcare system value may also influence adoption.
Regulatory compliance and NHS market access are distinct processes that should be planned together.
Canada presents a similar distinction between regulatory authorization and reimbursement.
Health Canada regulates medical device licensing, while public healthcare funding and reimbursement decisions frequently involve provincial and territorial healthcare systems.
Depending on the product, manufacturers may need to consider health technology assessments, provincial reimbursement policies, hospital procurement, and private insurance coverage.
A product authorized for sale in Canada may therefore require additional market access activities before widespread adoption becomes commercially viable.
Regulatory and reimbursement planning are often treated as separate activities, sometimes managed by different teams at different stages of development.
However, the two are closely connected.
Regulatory authorities evaluate whether a medical product meets applicable safety, performance, effectiveness, or benefit-risk requirements.
Payers and healthcare decision-makers evaluate additional considerations, including clinical value, medical necessity, comparative effectiveness, cost-effectiveness, and budget impact.
Although these assessments serve different purposes, they may depend on overlapping clinical and technical evidence.
For example, a clinical study designed primarily to support regulatory authorization may not collect the comparative outcomes, healthcare utilization information, or economic data needed to support reimbursement discussions.
If these requirements are identified only after a regulatory submission has been completed, the manufacturer may need to conduct additional studies, extend commercialization timelines, or absorb substantial unplanned expenses.
Integrating regulatory and reimbursement planning early creates an opportunity to develop evidence that supports both authorization and commercial adoption.
This does not mean every study must satisfy every regulator and payer. Rather, companies should identify the requirements of both groups before committing to expensive development and clinical programs.
Consider a hypothetical medical technology company developing an innovative diagnostic device.
The company invests heavily in engineering, software development, verification and validation, and clinical testing. After several years, it successfully obtains FDA clearance.
Only then does the company begin evaluating reimbursement.
It discovers that existing reimbursement codes may not adequately describe the service, insurers have limited coverage policies for the technology, and healthcare providers may be unable to recover the cost of using the device.
The company now faces additional evidence generation, payer engagement, and possible coding or payment development activities before its commercial model can achieve the anticipated results.
The product may be legally marketed, but its adoption is constrained by financial and healthcare system barriers.
Had the company evaluated reimbursement earlier, it might have adjusted its clinical study design, refined its target patient population, modified its commercial model, or prioritized markets with more favorable adoption conditions.
This illustrates a fundamental principle:
The cost of developing a regulatory and reimbursement strategy early is generally far less than the potential cost of discovering a major commercialization barrier after product development is complete.
For companies planning to commercialize medical products internationally, regulatory and reimbursement considerations should influence which markets are prioritized and when.
The United States may offer attractive commercial opportunities but require significant regulatory and payer evidence.
The European Union may provide access to multiple countries through a common regulatory framework, while reimbursement pathways differ across national healthcare systems.
The United Kingdom may offer opportunities through NHS adoption pathways, although clinical and economic evidence requirements can influence purchasing decisions.
Canada may be an attractive market for certain technologies, but manufacturers must consider both federal licensing requirements and provincial funding structures.
Other markets, including Australia, Brazil, Japan, and countries throughout Asia and the Middle East, introduce additional regulatory, reimbursement, and healthcare procurement considerations.
There is no single market entry sequence that is appropriate for every medical product.
An effective global strategy considers regulatory complexity, clinical evidence, reimbursement feasibility, market size, competition, commercialization costs, and the resources available to the manufacturer.
By evaluating these factors together, companies can make more informed decisions about where to invest, which markets to pursue first, and how to structure their development programs.
Ideally, both strategies should begin during the early stages of product development, before finalizing the intended use, clinical study design, and major commercialization investments.
At this stage, companies have greater flexibility to adjust their product positioning, technical requirements, evidence plans, and market priorities.
An integrated planning approach should include:
Together, these activities provide a stronger foundation for development planning, investment decisions, and commercial execution.
Since 1996, RQMIS has supported emerging and established medical product companies as they navigate regulatory requirements, quality management, clinical development, and international market access.
With headquarters in the United States and operations in the United Kingdom and European Union, RQMIS helps manufacturers evaluate regulatory pathways and develop practical strategies for bringing medical technologies to market.
Our services include:
By bringing these disciplines together, RQMIS helps clients understand not only what is required to obtain regulatory authorization, but also what may be necessary to support adoption and long-term commercial viability.
Medical product commercialization is not simply a regulatory exercise. It is a coordinated process involving product development, clinical evidence, quality management, healthcare economics, reimbursement, and market access.
Companies that begin with a clearly defined Regulatory Pathway Strategy and Insurance Reimbursement Plan are better positioned to identify risks, allocate resources effectively, and make informed decisions throughout development.
Most importantly, they can evaluate whether their product has a realistic path not only to regulatory authorization, but also to adoption by the healthcare systems and customers they intend to serve.
Regulatory authorization opens the door to the market. Reimbursement and market access planning help determine whether your product can succeed once it gets there
Are you developing a medical device, diagnostic technology, digital health solution, or other regulated medical product for the U.S., UK, EU, Canada, or international markets?
RQMIS can help you evaluate your regulatory pathway, identify reimbursement considerations, and develop a coordinated strategy aligned with your clinical, technical, and commercial objectives.
Contact RQMIS to discuss your regulatory and reimbursement planning needs.